Cannabinoids, The Heart of the Matter

GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the publication of a review article co-authored by GB Sciences and key collaborators in the Journal of the American Heart Association, which explains the potential medical benefits of using cannabinoid-based therapies for the treatment of heart diseases. GB Sciences’ own Chief Science Officer, Dr.?Andrea Small-Howard, joins co-authors including Dr.?Alexander Stokes, President of Makai Biotechnology, LLC, and Dr.?Helen Turner, VP of Innovation and Dean of the Division of Natural Sciences and Mathematics at?Chaminade University, in expounding on this very important subject in “Cannabinoids, the Heart of the Matter“. The link to the article is found at? While there have been recent studies supporting the use of cannabinoids for seizure disorders, most people and many scientists are not aware of the potential uses for cannabinoids in treating cardiac hypertrophy and other heart diseases.

With the recent FDA approval of GW Pharma’s cannabinoid-based drug, Epidiolex, people are becoming more aware that cannabinoid-based therapies can have significant medical benefits for patients with seizures caused by Lennox-Gastaut or Dravet Syndrome,” explains Dr. Small-Howard, “but we wanted to bring attention to the potential life-saving applications of cannabinoids for the treatment of heart conditions through the manipulation of specific-cannabinoid sensitive receptors.

In December of 2016, GB Sciences licensed patents on methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1, from Dr. Stokes of Makai Biotechnology. GB remains committed to cannabis-based therapies for heart disease, as demonstrated by their filing original patent applications on the use of myrcene-based complex mixtures for heart disease in May of 2017 and another patent application on cannabinoid and terpenoid-based complex mixtures for the treatment of heart disease through manipulation of cannabis-receptors in May of 2018.

John Poss, CEO of GB Sciences says,?“Heart disease is still the leading global cause of death, and cannabinoid-based therapeutics are a promising new option for its treatment. At GB Sciences, we are committed to broadening the scope of scientific research using novel applications of cannabinoid therapies and rigorously demonstrating their effectiveness.”

Leave a Reply

Your email address will not be published. Required fields are marked *